• In April 2026, Adagene Inc. announced it had entered a clinical collaboration with Incyte to test muzastotug (ADG126) with Incyte’s TGFβR2 × PD‑1 bispecific antibody INCA33890 in a Phase 1 trial for third‑line microsatellite stable colorectal cancer, including patients with and without liver metastases, with Incyte sponsoring and running the study.
• This collaboration highlights Incyte’s continued push into complex immuno‑oncology combinations and positions muzastotug as a potential backbone therapy in an area of high unmet need.
• We’ll now examine how this new immuno-oncology partnership with Adagene may influence Incyte’s high-expectation pipeline narrative and risk profile.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Incyte Investment Narrative Recap

To own Incyte, you need to be comfortable with a company still heavily tied to Jakafi while leaning on its oncology and immunology pipeline for diversification. The new Adagene collaboration fits that story but does not change the near term focus on upcoming data and regulatory milestones or the key risk that pipeline progress may not scale quickly enough to offset patent and pricing pressure.

The most relevant recent update here is Incyte’s appointment of Pablo Cagnoni as President and Global Head of R&D, alongside a refreshed late stage leadership team. That move, together with the Adagene tie up, reinforces how much the near term catalyst profile now rests on pipeline execution in oncology combinations and next generation immunology, at a time when R&D spend and expectations are both rising.

Yet beneath the collaboration headlines, investors should also be aware of the risk that...

Incyte's narrative projects $5.9 billion revenue and $1.5 billion earnings by 2028. This requires 8.9% yearly revenue growth and about a $629 million earnings increase from $870.9 million today.

Uncover how Incyte's forecasts yield a $100.10 fair value, a 4% upside to its current price.

Exploring Other Perspectives

While the Adagene deal speaks to experimental combo potential, the most optimistic analysts were already assuming about US$8.5 billion in 2029 revenue and US$2.2 billion in earnings, so you should expect that views on whether such targets remain realistic could shift meaningfully from here.

Explore 4 other fair value estimates on Incyte - why the stock might be worth 47% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Incyte research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Incyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Incyte's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.